专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110166081A1 Alpha-dystroglycan as a Protein Therapeutic 审中-公开
标题翻译： α-dystroglycan作为蛋白质治疗
公开(公告)号：US20110166081A1
公开(公告)日：2011-07-07
申请号：US12836874
申请日：2010-07-15
申请人： Kevin P. Campbell , Takako Moriguchi
发明人： Kevin P. Campbell , Takako Moriguchi
IPC分类号： A61K38/17 , A61P21/00 , C12P21/02
CPC分类号： A61K38/1703 , A61K9/0019 , A61K38/14
摘要： Disclosed is alpha-dystroglycan protein (alpha-DG) in glycosylated and functional form. The disclosed alpha-DG binds to the basal lamina and to the sarcolemma of muscle fibers and may be injected into muscle and incorporated into muscle fibers in order to restore membrane integrity where the muscle fibers comprise a dysfunctional alpha-DG protein. Alpha-DG as disclosed herein may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with or characterized by a dysfunctional alpha-DG, such as muscular dystrophy.
摘要翻译：公开了糖基化和功能形式的α-谷胱甘肽聚糖蛋白（α-DG）。所公开的α-DG结合基底层和肌纤维的肌膜，并且可以注射到肌肉中并且并入肌肉纤维中，以便恢复膜完整性，其中肌纤维包含功能障碍的α-DG蛋白。本文公开的α-DG可用于治疗与功能障碍性α-DG相关或特征在于肌营养不良症的疾病和病症的药物组合物和方法。

2. 发明授权

US5672694A .beta.-sarcoglycan nucleic acid sequence, and nucleic acid probes 失效
标题翻译： β-聚糖核酸序列和核酸探针
公开(公告)号：US5672694A
公开(公告)日：1997-09-30
申请号：US547182
申请日：1995-10-24
申请人： Kevin P. Campbell , Leland Lim , Franck Duclos , Yoshihide Sunada , Jacques S. Beckmann , Odile Broux , Fernando M. S. Tome , Michel Fardeau , Charles E. Jackson
发明人： Kevin P. Campbell , Leland Lim , Franck Duclos , Yoshihide Sunada , Jacques S. Beckmann , Odile Broux , Fernando M. S. Tome , Michel Fardeau , Charles E. Jackson
IPC分类号： A61K39/00 , C07K14/47 , C12Q1/68 , C07H19/00 , C07H21/02 , C07H21/04
CPC分类号： C07K14/4707 , C12Q1/6883 , A61K39/00 , C12Q2600/156 , C12Q2600/172
摘要： Disclosed herein is a substantially pure nucleic acid sequence encoding a mammalian 43 kDa non-dystrophin component (.beta.-sarcoglycan) of the dystrophin-glycoprotein complex. Also disclosed are immunogenic peptides which, when used to immunize a mammal, stimulate the production of antibodies which bind specifically to the .beta.-sarcoglycan. Mutations in the .beta.-sarcoglycan gene which are associated with autosomal recessive limb-girdle muscular dystrophy are also disclosed. The identification of such mutations enables the design of nucleic acid probes which hybridize specifically to a mutant form of .beta.-sarcoglycan, or the complement thereof, but not to the DNA of the wild-type form of the gene (or the complement thereof), under stringent hybridization conditions. Such probes are useful, for example, in connection with the diagnosis of autosomal recessive limb-girdle muscular dystrophy. In addition, the identification of such mutations enables the diagnosis of autosomal recessive limb-girdle muscular dystrophy through the use of direct DNA sequencing techniques.
摘要翻译：本文公开了编码肌营养不良蛋白 - 糖蛋白复合物的哺乳动物43kDa非肌营养不良蛋白成分（β-卡非糖）的基本上纯的核酸序列。还公开了免疫原性肽，其当用于免疫哺乳动物时，刺激特异性结合β-糖聚糖的抗体的产生。还公开了与常染色体隐性遗传性肢体肌营养不良症相关的β - 肌凝蛋白基因的突变。这种突变的鉴定使得能够设计与β-丝裂核糖苷或其补体的突变形式特异性杂交的核酸探针，而不与野生型形式的基因（或其补体）的DNA杂交，在严格的杂交条件下。这样的探针可用于例如与常染色体隐性性腰带肌营养不良症的诊断有关。此外，通过使用直接DNA测序技术，鉴定这种突变能够诊断常染色体隐性的腰带肌营养不良症。

3. 发明授权

US08119766B2 Increasing functional glycosylation of alpha-dystroglycan in the treatment of muscle degeneration 有权
标题翻译：增加α-dystrogly糖蛋白在肌肉退化治疗中的功能糖基化
公开(公告)号：US08119766B2
公开(公告)日：2012-02-21
申请号：US11143885
申请日：2005-06-02
申请人： Kevin P. Campbell , Rita Barresi
发明人： Kevin P. Campbell , Rita Barresi
IPC分类号： C07K1/00 , C07H21/02 , C07H21/04 , A61K48/00
CPC分类号： C12N9/1048 , A61K38/1709 , A61K48/00 , C07K14/4707
摘要： Disclosed is a method for the prevention and/or treatment of muscle degeneration. In this method, a subject recognized as having muscle degeneration is treated with a composition effective to increase functional glycosylation of α-dystroglycan in an affected tissue in the subject. Functional glycosylation is to be increased to an extent wherein the binding of α-dystroglycan to its ligands in the affected tissue is rescued to levels substantially similar to those in an evenly matched tissue unaffected by degeneration. One effective means for increasing functional glycosylation of α-dystroglycan in a subject includes increasing glycosyltransferase activity, such as LARGE or LARGE2 activity, in the muscle of the subject. Therapeutic glycosylated peptide compositions are also provided.
摘要翻译：公开了一种预防和/或治疗肌肉退化的方法。在该方法中，被认为具有肌肉退化的受试者用有效增加受试者的受影响组织中α-肌浆聚糖功能性糖基化的组合物进行治疗。功能性糖基化将被增加到其中α-dystroglylyc结合其受影响组织中的其配体的程度被挽救到基本上类似于不受退化影响的均匀匹配组织中的水平。用于增加受试者中α-谷胱甘肽聚糖功能糖基化的一种有效方法包括在受试者的肌肉中增加糖基转移酶活性，如LARGE或LARGE2活性。还提供了治疗性糖基化肽组合物。

4. 发明授权

US06365337B1 Genes encoding neuronal voltage-gated calcium channel gamma subunits 失效
标题翻译：编码神经元电压门控钙通道γ亚基的基因
公开(公告)号：US06365337B1
公开(公告)日：2002-04-02
申请号：US09123030
申请日：1998-07-27
申请人： Verity A. Letts , Wayne N. Frankel , Kevin P. Campbell , Ricardo Felix , Gloria Biddlecome
发明人： Verity A. Letts , Wayne N. Frankel , Kevin P. Campbell , Ricardo Felix , Gloria Biddlecome
IPC分类号： G01N33567
CPC分类号： C07K14/705 , G01N33/6872
摘要： Disclosed are mammalian nucleic acid sequences encoding a neuronal-specific subunit of a voltage-gated calcium channel. Specifically disclosed are &ggr;2, &ggr;3 and &ggr;4 subunits. In other aspects, the disclosure relates to expression vectors which encode neuronal-specific subunits, as well as cells containing such vectors. In other aspects, the disclosure relates to antigenic fusion proteins comprising at least a portion of a mammalian neuronal-specific subunit of a voltage-gated calcium channel. Such fusion proteins are useful, for example, in the production of antibodies specifically reactive with the subunits of the invention. The nucleic acid sequences of the invention find application, for example, in screening for compounds which modulate the activity of neuronal voltage-gated calcium channels and also in diagnostic methods for diagnosing the autoimmune disease Lambert-Eaton Syndrome, as well as diagnosing defects in &ggr; subunit genes of a patient with a neuronal disease such as epilepsy. An additional application of the nucleic acid sequences of the invention is in therapeutic methods of treatment for such disorders.
摘要翻译：公开了编码电压门控钙通道的神经元特异性亚基的哺乳动物核酸序列。具体公开的是γ2，γ3和γ4亚基。在其他方面，本公开涉及编码神经元特异性亚单位的表达载体以及含有该载体的细胞。在其他方面，本公开涉及包含电压门控钙通道的哺乳动物神经元特异性亚基的至少一部分的抗原性融合蛋白。这样的融合蛋白质可用于例如在与本发明的亚单位特异性反应的抗体的产生中。本发明的核酸序列可用于例如筛选调节神经元电压门控钙通道活性的化合物，以及用于诊断自身免疫疾病兰伯特 - 伊顿综合征的诊断方法，以及诊断伽马患有神经元疾病如癫痫患者的亚基基因。本发明的核酸序列的另外的应用是治疗这些疾病的治疗方法。

5. 发明授权

US4912202A Dihydropyridine receptor and antibodies thereto 失效
标题翻译：二氢吡啶受体及其抗体
公开(公告)号：US4912202A
公开(公告)日：1990-03-27
申请号：US1788
申请日：1987-01-08
申请人： Kevin P. Campbell , Toshiaki Imagawa , Albert T. Leung
发明人： Kevin P. Campbell , Toshiaki Imagawa , Albert T. Leung
IPC分类号： C07K14/705 , C07K16/28
CPC分类号： C07K14/705 , C07K16/28 , Y10S530/809
摘要： Monoclonal antibodies capable of immunoprecipitating labeled dihydropyridine receptor material from digitonin-solubilized skeletal muscle triads are disclosed. Said antibodies recognize a 170,000 dalton protein subunit of the dihydropyridine receptor.
摘要翻译：公开了能够从经丝氨酸溶解的骨骼肌三联体免疫沉淀标记的二氢吡啶受体材料的单克隆抗体。所述抗体识别二氢吡啶受体的170,000道尔顿蛋白亚基。

6. 发明授权

US4784955A Immunogen conjugates and the use thereof in a dihydropyridine assay 失效
标题翻译：免疫原共轭物及其在二氢吡啶试验中的应用
公开(公告)号：US4784955A
公开(公告)日：1988-11-15
申请号：US825572
申请日：1986-02-03
申请人： Kevin P. Campbell
发明人： Kevin P. Campbell
IPC分类号： G01N33/531 , G01N33/94 , G01N33/537 , G01N33/577
CPC分类号： G01N33/9453 , G01N33/531 , Y10S435/948 , Y10S436/808 , Y10S436/815 , Y10S436/822 , Y10S530/807 , Y10S530/808
摘要： Disclosed are 1,4-dihydropyridine immunogen conjugates of immunogenic carrier materials coupled to a 1,4-dihydropyridine derivative. Said conjugates are useful for the preparation of antibodies thereto which antibodies may be used in immunoassays for 1,4-dihydropyridine compounds. An affinity column useful for the purification of said antibodies is also disclosed.
摘要翻译：公开了与1,4-二氢吡啶衍生物偶联的免疫原性载体材料的1,4-二氢吡啶免疫原缀合物。所述缀合物可用于制备抗体，其抗体可用于1,4-二氢吡啶化合物的免疫测定。还公开了可用于纯化所述抗体的亲和柱。

7. 发明申请

US20110160219A1 Inhibitors of Phosphodiesterase Type 5A for Treating or Preventing Muscle Disease or the Symptoms Thereof in a Patient 审中-公开
标题翻译：磷酸二酯酶5A型抑制剂用于治疗或预防患者的肌肉病或其症状
公开(公告)号：US20110160219A1
公开(公告)日：2011-06-30
申请号：US13034938
申请日：2011-02-25
申请人： Kevin P. Campbell , Yvonne M. Kobayashi , Robert W. Crawford
发明人： Kevin P. Campbell , Yvonne M. Kobayashi , Robert W. Crawford
IPC分类号： A61K31/4985 , A61K31/519 , A61P21/00 , A61P43/00
CPC分类号： A61K31/519 , A61K31/4985 , A61K31/53 , A61K31/66
摘要： Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors.
摘要翻译：公开了用于治疗或预防肌肉疾病或其症状的药物组合物和方法。组合物通常包括并且该方法通常使用5A型磷酸二酯酶抑制剂。

8. 发明授权

US5733732A Methods for detecting primary adhalinopathy 失效
标题翻译：检测原发性腺瘤病的方法
公开(公告)号：US5733732A
公开(公告)日：1998-03-31
申请号：US582539
申请日：1996-01-03
申请人： Kevin P. Campbell , Steven L. Roberds , Yoshihide Sunada , Federica Piccolo , Marc Jeanpierre , Jean-Claude Kaplan
发明人： Kevin P. Campbell , Steven L. Roberds , Yoshihide Sunada , Federica Piccolo , Marc Jeanpierre , Jean-Claude Kaplan
IPC分类号： C12Q1/68 , C07H19/00 , C07H21/02 , C07H21/04
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： Disclosed herein are compositions and methods for the detection of primary adhalinopathy. More specifically, disclosed herein are nucleic acid probes which hybridize specifically, under stringent hybridization conditions, to a mutant adhalin gene or the complement thereof, but not to the corresponding region of a wild-type adhalin gene. Also disclosed are methods for the detection of a mutation in the human adhalin gene which is responsible for primary adhalinopathy. Such methods include the use of the nucleic acid probes of the invention for detection of the myopathy by hybridization, as well as detection by direct DNA sequencing techniques.
摘要翻译：本文公开了用于检测原发性腺瘤病的组合物和方法。更具体地，本文公开了在严格杂交条件下特异性与突变体阿达肝素基因或其互补序列而不是野生型腺恶素基因的相应区域杂交的核酸探针。还公开了用于检测负责原代腺病变的人腺酸基因突变的方法。这些方法包括使用本发明的核酸探针通过杂交检测肌病，以及通过直接DNA测序技术的检测。

9. 发明授权

US5686073A Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein 失效
标题翻译：针对43 KDA肌营养不良蛋白相关蛋白的多克隆和单克隆抗体
公开(公告)号：US5686073A
公开(公告)日：1997-11-11
申请号：US483278
申请日：1995-06-07
申请人： Kevin P. Campbell , Oxana B. Ibraghimov , James M. Ervasti , Cynthia J. Leveille
发明人： Kevin P. Campbell , Oxana B. Ibraghimov , James M. Ervasti , Cynthia J. Leveille
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C12P21/08 , G01N33/68 , C07K7/08
CPC分类号： C07K14/4707 , C07K14/4708 , C07K14/705 , C07K16/18 , C07K16/28 , G01N33/6887 , G01N33/6896 , A61K38/00 , A61K39/00 , C07K2317/34 , G01N2800/2878 , G01N2800/2885
摘要： Disclosed are methods for the preparation of polyclonal and monoclonal antibodies which bind specifically to a 43 kDa dystrophin-associated. The molecular weight of the 43 kDa protein is determined by electrophoretic separation under denaturing conditions, followed by transfer to a solid support and staining with wheat germ agglutinin. The method includes a step in which the peptide PKNMTPYRSPPPYVP (SEQ ID NO: 15) is administered to stimulate an immune response. Also disclosed are polyclonal and monoclonal antibodies which bind specifically to the 43 kDa dystrophin-associated protein.
摘要翻译：公开了制备与43kDa肌营养不良蛋白相关的特异性结合的多克隆和单克隆抗体的方法。通过在变性条件下的电泳分离测定43kDa蛋白质的分子量，随后转移到固体支持物上并用小麦胚芽凝集素染色。该方法包括施用肽PKNMTPYRSPPPYVP（SEQ ID NO：15）以刺激免疫应答的步骤。还公开了与43kDa肌营养不良蛋白相关蛋白特异性结合的多克隆和单克隆抗体。

10. 发明授权

US5449616A Nucleic acid encoding dystrophin-associated protein 失效
标题翻译：编码肌营养不良蛋白相关蛋白的核酸
公开(公告)号：US5449616A
公开(公告)日：1995-09-12
申请号：US123161
申请日：1993-09-16
申请人： Kevin P. Campbell , Steven L. Roberds , Richard D. Anderson
发明人： Kevin P. Campbell , Steven L. Roberds , Richard D. Anderson
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/705 , C07K16/18 , C07K16/28 , C12P21/08 , G01N33/68 , C07K14/435 , C12N5/10 , C12N15/12 , C12N15/63
CPC分类号： C07K14/4708 , C07K14/4707 , C07K14/705 , C07K16/18 , C07K16/28 , G01N33/6887 , G01N33/6896 , A61K38/00 , A61K39/00 , C07K2317/34 , G01N2800/2878 , G01N2800/2885
摘要： Disclosed are nucleic acid sequences encoding components of the dystrophin-glycoprotein complex. The components include dystroglycan, the 50 kDa protein component and the 59 kDa protein component. Also disclosed are compositions and methods which relate to the disclosed sequences.
摘要翻译：公开了编码肌营养不良蛋白 - 糖蛋白复合物组分的核酸序列。组分包括肌浆聚糖，50kDa蛋白质组分和59kDa蛋白质组分。还公开了与公开的序列相关的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式